H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)

September 9, 2026 7:28 AM

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $30.00 price target on Generate Biomedicines (NASDAQ: GENB).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found